Fierce 15 highlights pre-commercial biotech companies driving the next generation of therapies for patients worldwide
Cambridge, UK, 22 September 2025: TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates to combat neurodegenerative diseases, today announced that it has been named as one of Fierce Biotech’s 2025’s ‘Fierce 15’ for 2025. The selection recognises the Company as one of the most innovative and promising private biotechnology companies in the industry.
TRIMTECH is addressing the urgent need for cost-…
Oxford, UK – 22nd September 2025. OGT, a leading global provider of genomic diagnostic and research solutions, announced today that the U.S. Food and Drug Administration (FDA) has granted their De Novo Classification Request for the CytoCell® KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic (CDx) for Syndax’s first-in-class menin inhibitor, REVUFORJ® (revumenib). Revuforj is FDA approved for the treatment of relapsed or refractory (R/R) acute leukaemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and paediatric patients one year and older.
OGT’s…
• Mohit Rawat appointed CEO, bringing deep biopharma leadership and a track record of driving innovations in drug discovery to commercial and transactional success; former CEO Robin Carr transitions to new CTO role
• Expanded senior team across clinical, CMC, regulatory and business development in the US and UK
• Global leader in developing a novel and highly differentiated payload class for ADCs, NMTi (N-myristoyltransferase inhibitors), to address the critical need to overcome payload resistance and improve tolerability
• On track to enter the clinic with lead NMTi-ADC candidate, following…
There are many different types of cells in the brain. We know that in Parkinson’s, brain cells that produce dopamine become damaged and start to die over time. However, it’s possible that other types of brain cells could also become damaged, and they may even play a role in why dopamine cells become unwell.
Dr Nataly Hastings at Cellestial Health is leading a team of researchers to explore how a previously overlooked type of brain cell, called an astrocyte, could be involved in Parkinson’s. Astrocytes are star-shaped brain cells that form large networks in the brain. Within these networks,…
KRAS is one of the most frequently mutated oncogenes in human cancers. Once thought “undruggable,” recent scientific advances have enabled the development of therapies targeting KRAS mutations, especially G12C, G12D, and G13D.
At Medicilon, we provide integrated preclinical services to support KRAS-targeted drug discovery and development:
✅ Drug discovery
✅ CMC research (API + formulation)
✅ Pharmacodynamics study
✅ Pharmacokinetics (PK) analysis
✅ Safety evaluation
Understanding KRAS: https://pubmed.ncbi.nlm.nih.gov/31649840/
KRAS functions as a molecular switch, cycling between GDP-…
Amsbio offers a growing list of experimental cell lines, recombinant proteins, and screening services to help accelerate the development of new CAR-T cell therapies. Personalized treatment for cancer reached a new milestone in 2017 with the FDA approval of CAR-T cell therapy for treatment of children and adolescents with B cell acute lymphoblastic leukemia (ALL).
Amsbio Business Development Manager – Dr Maja Petkovic commented “The first FDA approved treatments were CAR-T cells directed against the B cell protein CD19. This success inspired new research that demonstrated CAR-T cell…
San Diego, CA – September 15, 2025 – Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its AbZelectPRO™ cell line development (CLD) platform with the launch of two next-generation Glutamine Synthetase (“GS”) knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins. The addition of the new GS knockout cell lines will further enhance speed, scalability, and flexibility for biopharma customers.Named AbZelectPRO™-KO and AbZelectPRO™-KO+, the new GS knockout platforms are available as a…
LONDON, UK and BOSTON, MA - September 18, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Alltrna and is pleased to announce the placement of David (Dave) Hava, Ph.D., as Chief Scientific Officer (CSO).Alltrna, a Flagship Pioneering company, is unlocking transfer RNA (tRNA) biology and pioneering tRNA medicines to regulate the protein universe and resolve disease.With nearly two decades of drug development experience, Dr. Hava has led multidisciplinary teams that…
Victoria House, a newly restored Grade II listed building in London’s Bloomsbury Square, officially opened its doors yesterday (16 September) as a state-of-the-art life sciences hub.
Developed by Oxford Properties and Pioneer Group, converted by CW Architects and delivered by contractor Wates, the 300,000 sq ft facility redefines the capital’s science and technology landscape. The building offers a unique combination of lab-enabled, fully fitted and incubator laboratory space and serviced offices within highly technical, tailored infrastructure – supporting the full lifecycle of life sciences…
Learnings From Pop and Rap Stars for Genesis There is an old saying, popularised more recently by Pitbull and Christina Aguilera, that goes, ‘Ask for money, get advice; ask for advice, get money twice.’ This has perhaps never been truer than in the life sciences sector over recent times when advice has been far more freely given than investment. This is the motivation for the new Company Showcase stream introduced at Genesis this year, which will include fifty pitches from growing companies on their dealmaking journey.Striving to be EfficientFor several years now the desire to be…